Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.56 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21944599 | 0.87 | APP (0.56) | APPMAOBMRGPRX4NR4A2 | |
| SCHEMBL5511918 | 0.86 | IDO1 (0.54) | IDO1RAB9APTGDR2S1PR1SLC6A4 | |
| SCHEMBL5517700 | 0.85 | IDO1 (0.55) | IDO1PTGDR2S1PR1SLC6A4GPR84 | |
| SCHEMBL21945019 | 0.82 | IDO1 (0.55) | IDO1PTGDR2S1PR1SLC6A4GPR84 | |
| SCHEMBL18002184 | 0.82 | MAOB (0.60) | IDO1RAB9APTGDR2S1PR1MAOB | |
| SCHEMBL4697694 | 0.81 | MRGPRX4 (0.53) | APPPTGDR2MAOBMRGPRX4 | |
| SCHEMBL27533351 | 0.80 | RAB9A (0.53) | IDO1RAB9A | |
| SCHEMBL22964317 | 0.78 | MAOB (0.58) | APPMAOBNR4A2 | |
| SCHEMBL5505912 | 0.78 | IDO1 (0.60) | IDO1PTGDR2S1PR1SLC6A4GPR84 | |
| SCHEMBL4700356 | 0.77 | NR4A2 (0.68) | IDO1APPMAOBMRGPRX4NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | IDO1 2430/4885APP 2183/4885RAB9A 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.